山东大学学报（医学版） ›› 2017, Vol. 55 ›› Issue (1): 26-32.doi: 10.6040/j.issn.1671-7554.0.2016.1334
杨冬梓,麦卓瑶
YANG Dongzi, MAI Zhuoyao
摘要： 35岁后多囊卵巢综合征(PCOS)患者的卵巢储备较之同龄人可能有一定的优势。在行辅助生育技术(ART)过程中,40岁前的获卵数往往高于同龄非PCOS人群,40岁以后PCOS患者同样有卵泡质量及胚胎发育潜能不足的问题,对ART助孕结局产生不利影响。现有资料表明,PCOS患者在40岁以后的临床妊娠率、活产率与同龄非PCOS人群的变化趋势一样,同时其代谢、内分泌因素对妊娠结局的负面影响仍然存在。
中图分类号:
| [1] McCartney CR, Marshall JC. Clinical practice. Polycystic ovary syndrome[J]. N Engl J Med, 2016, 375(1): 54-64. [2] 沈文娟, 张跃辉, 匡洪影, 等. 多囊卵巢综合征治疗的研究现状[J]. 中华妇产科杂志, 2012, 47(1): 67-70. [3] Somigliana E, Paffoni A, Busnelli A, et al. Age-related infertility and unexplained infertility: an intricate clinical dilemma[J]. Hum Reprod, 2016, 31(7): 1390-1396. [4] Broekmans FJ, Knauff EA, te Velde ER, et al. Female reproductive ageing: current knowledge and future trends[J]. Trends Endocrinol Metab, 2007, 18(2): 58-65. [5] Richardson MC, Guo M, Fauser BC, et al. Environmental and developmental origins of ovarian reserve[J]. Hum Reprod Update, 2014, 20(3): 353-369. [6] te Velde ER, Scheffer GJ, Dorland M, et al. Developmental and endocrine aspects of normal ovarian aging[J]. Mol Cell Endocrinol, 1998, 145(1-2): 67-73. [7] Qiao J, Wang ZB, Feng HL, et al. The root of reduced fertility in aged women and possible therapentic options: current status and future perspects[J]. Mol Aspects Med, 2014, 38: 54-85. doi: 10.1016/j.mam.2013.06.001. [8] Rabinowitz M, Ryan A, Gemelos G, et al. Origins and rates of aneuploidy in human blastomeres[J]. Fertil Steril, 2012, 97(2): 395-401. [9] Monniaux D, Clement F, Dalbies-Tran R, et al. The ovarian reserve of primordial follicles and the dynamic reserve of antral growing follicles: what is the link?[J] Biol Reprod, 2014, 90(4): 85. doi: 10.1095/biolreprod.113.117077. [10] Jeppesen JV, Anderson RA, Kelsey TW, et al. Which follicles make the most anti-Mullerian hormone in humans? Evidence for an abrupt decline in AMH production at the time of follicle selection[J]. Mol Hum Reprod, 2013, 19(8): 519-527. [11] Cui Y, Shi Y, Cui L, et al. Age-specific serum antimüllerian hormone levels in women with and without polycystic ovary syndrome[J]. Fertil Steril, 2014, 102(1): 230-236. [12] Aksglaede L, Sorensen K, Boas M, et al. Changes in anti-Mullerian hormone(AMH)throughout the life span: a population-based study of 1027 healthy males from birth(cord blood)to the age of 69 years[J]. J Clin Endocrinol Metab, 2010, 95(12): 5357-5364. [13] Wellons MF, Bates GW, Schreiner PJ, et al. Antral follicle count predicts natural menopause in a population-based sample: the Coronary Artery Risk Development in Young Adults Womens Study[J]. Menopause, 2013, 20(8): 825-830. [14] Hansen KR, Hodnett GM, Knowlton N, et al. Correlation of ovarian reserve tests with histologically determined primordial follicle number[J]. Fertil Steril, 2011, 95(1): 170-175. [15] Xita N, Tsatsoulis A. Review: fetal programming of polycystic ovary syndrome by androgen excess: evidence from experimental, clinical, and genetic association studies[J]. J Clin Endocrinol Metab, 2006, 91(5): 1660-1666. [16] Webber LJ, Stubbs S, Stark J, et al. Formation and early development of follicles in the polycystic ovary[J]. Lancet, 2003, 362(9389): 1017-1021. [17] Hudecova M, Holte J, Olovsson M, et al. Long-term follow-up of patients with polycystic ovary syndrome: reproductive outcome and ovarian reserve[J]. Hum Reprod, 2009, 24(5): 1176-1183. [18] Catteau-Jonard S, Jamin SP, Leclerc A, et al. Anti-Mullerian hormone, its receptor, FSH receptor, and androgen receptor genes are overexpressed by granulosa cells from stimulated follicles in women with polycystic ovary syndrome[J]. J Clin Endocrinol Metab, 2008, 93(11): 4456-4461. [19] Tehrani FR, Solaymani-Dodaran M, Hedayati M, et al. Is polycystic ovary syndrome an exception for reproductive aging?[J]. Hum Reprod, 2010, 25(7): 1775-1781. [20] Wiser A, Shalom-Paz E, Hyman JH, et al. Age-related normogram for antral follicle count in women with polycystic ovary syndrome[J]. Reprod Biomed Online, 2013, 27(4): 414-418. [21] Webber LJ, Stubbs SA, Stark J, et al. Prolonged survival in culture of preantral follicles from polycystic ovaries[J]. J Clin Endocrinol Metab, 2007, 92(5): 1975-1978. [22] Schmidt J, Brannstrom M, Landin-Wilhelmsen K, et al. Reproductive hormone levels and anthropometry in postmenopausal women with polycystic ovary syndrome(PCOS): a 21-year follow-up study of women diagnosed with PCOS around 50 years ago and their age-matched controls[J]. J Clin Endocrinol Metab, 2011, 96(7): 2178-2185. [23] Wild S, Pierpoint T, Jacobs H, et al. Long-term consequences of polycystic ovary syndrome: results of a 31 year follow-up study[J]. Hum Fertil(Camb), 2000, 3(2): 101-105. [24] May-Panloup P, Boucret L, Chao de la Barca JM, et al. Ovarian ageing: the role of mitochondria in oocytes and follicles[J]. Hum Reprod Update, 2016, 22(6):725-743. [25] Qiao J, Feng HL. Extra- and intra-ovarian factors in polycystic ovary syndrome: impact on oocyte maturation and embryo developmental competence[J]. Hum Reprod Update, 2011, 17(1): 17-33. [26] Dumesic DA, Abbott DH. Implications of polycystic ovary syndrome on oocyte development[J]. Semin Reprod Med, 2008, 26(1): 53-61. [27] Dumesic DA, Padmanabhan V, Abbott DH. Polycystic ovary syndrome and oocyte developmental competence[J]. Obstet Gynecol Surv, 2008, 63(1): 39-48. [28] Wood JR, Dumesic DA, Abbott DH, et al. Molecular abnormalities in oocytes from women with polycystic ovary syndrome revealed by microarray analysis[J]. J Clin Endocrinol Metab, 2007, 92(2): 705-713. [29] Heijnen EM, Eijkemans MJ, Hughes EG, et al. A meta-analysis of outcomes of conventional IVF in women with polycystic ovary syndrome[J]. Hum Reprod Update, 2006, 12(1): 13-21. [30] Sigala J, Sifer C, Dewailly D, et al. Is polycystic ovarian morphology related to a poor oocyte quality after controlled ovarian hyperstimulation for intracytoplasmic sperm injection? Results from a prospective, comparative study[J]. Fertil Steril, 2015, 103(1): 112-118. [31] Child TJ, Abdul-Jalil AK, Gulekli B, et al. In vitro maturation and fertilization of oocytes from unstimulated normal ovaries, polycystic ovaries, and women with polycystic ovary syndrome[J]. Fertil Steril, 2001, 76(5): 936-942. [32] Jonard S, Dewailly D. The follicular excess in polycystic ovaries, due to intra-ovarian hyperandrogenism, may be the main culprit for the follicular arrest[J]. Hum Reprod Update, 2004, 10(2): 107-117. [33] Hughesdon PE. Morphology and morphogenesis of the stein-leventhal ovary and of so-called “hyperthecosis”[J]. Obstet Gynecol Surv, 1982, 37(2): 59-77. [34] Dewailly D, Catteau-Jonard S, Reyss AC, et al. The excess in 2-5 mm follicles seen at ovarian ultrasonography is tightly associated to the follicular arrest of the polycystic ovary syndrome[J]. Hum Reprod, 2007, 22(6): 1562-1566. [35] Durlinger AL, Gruijters MJ, Kramer P, et al. Anti-Mullerian hormone inhibits initiation of primordial follicle growth in the mouse ovary[J]. Endocrinology, 2002, 143(3): 1076-1084. [36] Carlsson IB, Scott JE, Visser JA, et al. Anti-Mullerian hormone inhibits initiation of growth of human primordial ovarian follicles in vitro[J]. Hum Reprod, 2006, 21(9): 2223-2227. [37] Stubbs SA, Hardy K, Da Silva-Buttkus P, et al. Anti-müllerian hormone protein expression is reduced during the initial stages of follicle development in human polycystic ovaries[J]. J Clin Endocrinol Metab, 2005, 90(10): 5536-5543. [38] Hsueh AJ, Kawamura K, Cheng Y, et al. Intraovarian control of early folliculogenesis[J]. Endocr Rev, 2015, 36(1): 1-24. [39] Bhide P, Dilgil M, Gudi A, et al. Each small antral follicle in ovaries of women with polycystic ovary syndrome produces more antimullerian hormone than its counterpart in a normal ovary: an observational cross-sectional study[J]. Fertil Steril, 2015, 103(2): 537-541. [40] Das M, Gillott DJ, Saridogan E, et al. Anti-mullerian hormone is increased in follicular fluid from unstimulated ovaries in women with polycystic ovary syndrome[J]. Hum Reprod, 2008, 23(9): 2122-2126. [41] Dewailly D, Robin G, Peigne M, et al. Interactions between androgens, FSH, anti-mullerian hormone and estradiol during folliculogenesis in the human normal and polycystic ovary[J]. Hum Reprod Update, 2016, 22(6):709-724. [42] Grossman MP, Nakajima ST, Fallat ME, et al. Mullerian-inhibiting substance inhibits cytochrome P450 aromatase activity in human granulosa lutein cell culture[J]. Fertil Steril, 2008, 89(5 Suppl): 1364-1370. [43] Pierre A, Peigne M, Grynberg M, et al. Loss of LH-induced down-regulation of anti-Mullerian hormone receptor expression may contribute to anovulation in women with polycystic ovary syndrome[J]. Hum Reprod, 2013, 28(3): 762-769. [44] Grynberg M, Pierre A, Rey R, et al. Differential regulation of ovarian anti-mullerian hormone(AMH)by estradiol through alpha- and beta-estrogen receptors[J]. J Clin Endocrinol Metab, 2012, 97(9): E1649-E1657. [45] Catteau-Jonard S, Pigny P, Reyss AC, et al. Changes in serum anti-mullerian hormone level during low-dose recombinant follicular-stimulating hormone therapy for anovulation in polycystic ovary syndrome[J]. J Clin Endocrinol Metab, 2007, 92(11): 4138-4143. [46] Xi W, Yang Y, Mao H, et al. Circulating anti-mullerian hormone as predictor of ovarian response to clomiphene citrate in women with polycystic ovary syndrome[J]. J Ovarian Res, 2016, 9: 3. [47] Koninger A, Sauter L, Edimiris P, et al. Predictive markers for the FSH sensitivity of women with polycystic ovarian syndrome[J]. Hum Reprod, 2014, 29(3): 518-524. [48] Mumford SL, Legro RS, Diamond MP, et al. Baseline AMH level associated with ovulation following ovulation induction in women with polycystic ovary syndrome[J]. J Clin Endocrinol Metab, 2016, 101(9): 3288-3296. [49] Ellakwa HE, Sanad ZF, Hamza HA, et al. Predictors of patient responses to ovulation induction with clomiphene citrate in patients with polycystic ovary syndrome experiencing infertility[J]. Int J Gynaecol Obstet, 2016, 133(1): 59-63. [50] Hudecova M, Holte J, Moby L, et al. Androgen levels, insulin sensitivity, and early insulin response in women with polycystic ovary syndrome: a long-term follow-up study[J]. Fertil Steril, 2011, 95(3): 1146-1148. [51] Guido M, Belosi C, Selvaggi L, et al. The effect of age on the ovarian response to gonadotropin and on pregnancy rate in polycystic ovary syndrome[J]. Gynecol Endocrinol, 2003, 17(3): 215-221. [52] Mellembakken JR, Berga SL, Kilen M, et al. Sustained fertility from 22 to 41 years of age in women with polycystic ovarian syndrome[J]. Hum Reprod, 2011, 26(9): 2499-2504. [53] Kalra SK, Ratcliffe SJ, Dokras A. Is the fertile window extended in women with polycystic ovary syndrome? Utilizing the society for assisted reproductive technology registry to assess the impact of reproductive aging on live-birth rate[J]. Fertil Steril, 2013, 100(1): 208-213. [54] Hwang YI, Cha SW, Song IO, et al. Fertility of patients with polycystic ovary syndrome undergoing in vitro fertilization by age[J]. Int J Gynaecol Obstet, 2016, 35(1):91-95. [55] Delvigne A, Rozenberg S. Epidemiology and prevention of ovarian hyperstimulation syndrome(OHSS): a review[J]. Hum Reprod Update, 2002, 8(6): 559-577. [56] Koivunen R, Pouta A, Franks S, et al. Fecundability and spontaneous abortions in women with self-reported oligo-amenorrhea and/or hirsutism: Northern Finland Birth Cohort 1966 Study[J]. Hum Reprod, 2008, 23(9): 2134-2139. [57] West S, Vahasarja M, Bloigu A, et al. The impact of self-reported oligo-amenorrhea and hirsutism on fertility and lifetime reproductive success: results from the Northern Finland Birth Cohort 1966[J]. Hum Reprod, 2014, 29(3): 628-633. [58] Dicker D, Goldman JA, Ashkenazi J, et al. Age and pregnancy rates in in vitro fertilization[J]. J In Vitro Fert Embryo Transf, 1991, 8(3): 141-144. [59] Dor J, Seidman DS, Ben-Shlomo I, et al. Cumulative pregnancy rate following in-vitro fertilization: the significance of age and infertility aetiology[J]. Hum Reprod, 1996, 11(2): 425-428. [60] Gonzalez-Foruria I, Penarrubia J, Borras A, et al. Age, independent from ovarian reserve status, is the main prognostic factor in natural cycle in vitro fertilization[J]. Fertil Steril, 2016, 106(2): 342-347. [61] Shea LO, Hughes C, Mocanu EV. Advanced maternal age and assisted reproductive technologies in an irish population[J]. Ir Med J, 2015, 108(8): 243-246. [62] Yan J, Wu K, Tang R, et al. Effect of maternal age on the outcomes of in vitro fertilization and embryo transfer(IVF-ET)[J]. Sci China Life Sci, 2012, 55(8): 694-698. |
| [1] | 万文静,高姗姗. 低分子肝素在生殖领域的应用[J]. 山东大学学报 (医学版), 2025, 63(6): 117-124. |
| [2] | 韩馨玮,牛月,魏代敏. 激素替代方案准备内膜的冻胚移植前雌激素治疗时间对新生儿体质量的影响[J]. 山东大学学报 (医学版), 2025, 63(11): 46-52. |
| [3] | 杜娟,李秀芳,李元美,王慧丹. 孕康颗粒对冻融胚胎移植周期妊娠结局的影响[J]. 山东大学学报 (医学版), 2024, 62(7): 84-90. |
| [4] | 赵圣蕊,曲慧灵,许鑫鑫,张芳芳,颜磊. 体外受精/卵胞浆内单精子注射-胚胎移植后稽留流产采用药物流产和清宫术效果比较[J]. 山东大学学报 (医学版), 2024, 62(2): 69-74. |
| [5] | 王玉淼,崔晓霈,张红雨. 高龄老年新型冠状病毒肺炎患者应用抗凝治疗的短期疗效和安全性[J]. 山东大学学报 (医学版), 2024, 62(12): 21-31. |
| [6] | 李军秀,袁莹莹,黄凌燕,赵君利. 子宫内膜CD38表达对胚胎移植前抗炎治疗的临床价值[J]. 山东大学学报 (医学版), 2023, 61(8): 54-60. |
| [7] | 刘昶,王倩男,张悦,陈忠绍,褚然,姚舒. 卵巢交界性肿瘤保留生育功能术后肿瘤预后及妊娠结局[J]. 山东大学学报 (医学版), 2023, 61(8): 61-66. |
| [8] | 许月明,张杰,姜蕾,尹力,赵畔,许欣,郝桂敏. 扳机日孕酮升高与获卵数对辅助生殖技术新鲜周期妊娠结局的影响[J]. 山东大学学报 (医学版), 2023, 61(5): 44-50. |
| [9] | 赵元元,路军涛,吴小华. 人脐带间充质干细胞外泌体miR-100对多囊卵巢综合征患者颗粒细胞炎症的影响[J]. 山东大学学报 (医学版), 2023, 61(5): 51-58. |
| [10] | 戚丹,张曦,于倩,崔琳琳,颜磊. 子宫内膜增生症及早期子宫内膜癌保留生育功能后冻胚移植妊娠结局[J]. 山东大学学报 (医学版), 2023, 61(4): 56-63. |
| [11] | 王园园,孙云. 合并新型冠状病毒肺炎的维持性血液透析患者死亡危险因素[J]. 山东大学学报 (医学版), 2023, 61(11): 68-73. |
| [12] | 张丽霞,田一正,吕尚格,张亚男,颜磊. GnRH-a预处理对子宫内膜异位症患者替代方案冻胚移植结局的影响[J]. 山东大学学报 (医学版), 2023, 61(10): 63-68. |
| [13] | 慈倩倩,武胜英,万秋花,马运荣,赵建文,张健. 10 265例高龄孕妇的产前筛查与诊断方法分析[J]. 山东大学学报 (医学版), 2023, 61(1): 51-57. |
| [14] | 石玉华,潘烨,谢燕秋. 胚胎冷冻保存技术及进展[J]. 山东大学学报 (医学版), 2022, 60(9): 12-18. |
| [15] | 颜磊,岳彩欣,刘懿淳. 子宫内膜异位症的生育力保护[J]. 山东大学学报 (医学版), 2022, 60(9): 31-34. |
|
||
